Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors

H. J.N. Andreyev, P. Scott-Mackie, D. Cunningham, V. Nicolson, A. R. Norman, S. S. Badve, A. Iveson, M. C. Nicolson

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Purpose and Methods: Twenty-four patients with rapidly progressive neuroendocrine tumors were treated with a new regimen of continuous infusion fluorouracil for 20 weeks (200 mg/m2/d) together with interferon alfa-2b (5 MU three times per week). Maintenance interferon alfa at the same dose was continued after the initial 20-week period. Results: Of 15 patients with carcinoid tumors, seven (47%) had an objective response, with a median duration of 20.5 months (range, 8.5 to 41), and five (33%) had stabilization of disease for between 3.5 and 42 months. Improvement in symptoms was reported by 10 patients (67%). Three early deaths occurred, all in patients with advanced disease. Of nine patients with neuroendocrine tumors other than carcinoid, three (33%) had an objective response that lasted 2.5 to 24.5 months, and five had disease stabilization for between 2.5 and 16 months. Conclusion: These data, particularly in respect to carcinoid tumors, are encouraging, especially since serious complications from treatment were limited. This regimen is not generally toxic, is well tolerated, and offers useful palliation and symptom control in patients with disease that does not respond to simple pharmacologic manipulations.

Original languageEnglish (US)
Pages (from-to)1486-1492
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number6
DOIs
StatePublished - Jun 1995

Fingerprint

interferon alfa-2b
Neuroendocrine Tumors
Fluorouracil
Carcinoid Tumor
Interferon-alpha
Poisons
Maintenance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. / Andreyev, H. J.N.; Scott-Mackie, P.; Cunningham, D.; Nicolson, V.; Norman, A. R.; Badve, S. S.; Iveson, A.; Nicolson, M. C.

In: Journal of Clinical Oncology, Vol. 13, No. 6, 06.1995, p. 1486-1492.

Research output: Contribution to journalArticle

Andreyev, HJN, Scott-Mackie, P, Cunningham, D, Nicolson, V, Norman, AR, Badve, SS, Iveson, A & Nicolson, MC 1995, 'Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors', Journal of Clinical Oncology, vol. 13, no. 6, pp. 1486-1492. https://doi.org/10.1200/JCO.1995.13.6.1486
Andreyev, H. J.N. ; Scott-Mackie, P. ; Cunningham, D. ; Nicolson, V. ; Norman, A. R. ; Badve, S. S. ; Iveson, A. ; Nicolson, M. C. / Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 6. pp. 1486-1492.
@article{8591edc0b525451c9a8b2c8729aebd6c,
title = "Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors",
abstract = "Purpose and Methods: Twenty-four patients with rapidly progressive neuroendocrine tumors were treated with a new regimen of continuous infusion fluorouracil for 20 weeks (200 mg/m2/d) together with interferon alfa-2b (5 MU three times per week). Maintenance interferon alfa at the same dose was continued after the initial 20-week period. Results: Of 15 patients with carcinoid tumors, seven (47{\%}) had an objective response, with a median duration of 20.5 months (range, 8.5 to 41), and five (33{\%}) had stabilization of disease for between 3.5 and 42 months. Improvement in symptoms was reported by 10 patients (67{\%}). Three early deaths occurred, all in patients with advanced disease. Of nine patients with neuroendocrine tumors other than carcinoid, three (33{\%}) had an objective response that lasted 2.5 to 24.5 months, and five had disease stabilization for between 2.5 and 16 months. Conclusion: These data, particularly in respect to carcinoid tumors, are encouraging, especially since serious complications from treatment were limited. This regimen is not generally toxic, is well tolerated, and offers useful palliation and symptom control in patients with disease that does not respond to simple pharmacologic manipulations.",
author = "Andreyev, {H. J.N.} and P. Scott-Mackie and D. Cunningham and V. Nicolson and Norman, {A. R.} and Badve, {S. S.} and A. Iveson and Nicolson, {M. C.}",
year = "1995",
month = "6",
doi = "10.1200/JCO.1995.13.6.1486",
language = "English (US)",
volume = "13",
pages = "1486--1492",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors

AU - Andreyev, H. J.N.

AU - Scott-Mackie, P.

AU - Cunningham, D.

AU - Nicolson, V.

AU - Norman, A. R.

AU - Badve, S. S.

AU - Iveson, A.

AU - Nicolson, M. C.

PY - 1995/6

Y1 - 1995/6

N2 - Purpose and Methods: Twenty-four patients with rapidly progressive neuroendocrine tumors were treated with a new regimen of continuous infusion fluorouracil for 20 weeks (200 mg/m2/d) together with interferon alfa-2b (5 MU three times per week). Maintenance interferon alfa at the same dose was continued after the initial 20-week period. Results: Of 15 patients with carcinoid tumors, seven (47%) had an objective response, with a median duration of 20.5 months (range, 8.5 to 41), and five (33%) had stabilization of disease for between 3.5 and 42 months. Improvement in symptoms was reported by 10 patients (67%). Three early deaths occurred, all in patients with advanced disease. Of nine patients with neuroendocrine tumors other than carcinoid, three (33%) had an objective response that lasted 2.5 to 24.5 months, and five had disease stabilization for between 2.5 and 16 months. Conclusion: These data, particularly in respect to carcinoid tumors, are encouraging, especially since serious complications from treatment were limited. This regimen is not generally toxic, is well tolerated, and offers useful palliation and symptom control in patients with disease that does not respond to simple pharmacologic manipulations.

AB - Purpose and Methods: Twenty-four patients with rapidly progressive neuroendocrine tumors were treated with a new regimen of continuous infusion fluorouracil for 20 weeks (200 mg/m2/d) together with interferon alfa-2b (5 MU three times per week). Maintenance interferon alfa at the same dose was continued after the initial 20-week period. Results: Of 15 patients with carcinoid tumors, seven (47%) had an objective response, with a median duration of 20.5 months (range, 8.5 to 41), and five (33%) had stabilization of disease for between 3.5 and 42 months. Improvement in symptoms was reported by 10 patients (67%). Three early deaths occurred, all in patients with advanced disease. Of nine patients with neuroendocrine tumors other than carcinoid, three (33%) had an objective response that lasted 2.5 to 24.5 months, and five had disease stabilization for between 2.5 and 16 months. Conclusion: These data, particularly in respect to carcinoid tumors, are encouraging, especially since serious complications from treatment were limited. This regimen is not generally toxic, is well tolerated, and offers useful palliation and symptom control in patients with disease that does not respond to simple pharmacologic manipulations.

UR - http://www.scopus.com/inward/record.url?scp=0029040266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029040266&partnerID=8YFLogxK

U2 - 10.1200/JCO.1995.13.6.1486

DO - 10.1200/JCO.1995.13.6.1486

M3 - Article

C2 - 7751896

AN - SCOPUS:0029040266

VL - 13

SP - 1486

EP - 1492

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -